GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medartis Holding AG (XSWX:MED) » Definitions » EV-to-EBIT

Medartis Holding AG (XSWX:MED) EV-to-EBIT : 120.46 (As of May. 27, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Medartis Holding AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Medartis Holding AG's Enterprise Value is CHF949.7 Mil. Medartis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was CHF7.9 Mil. Therefore, Medartis Holding AG's EV-to-EBIT for today is 120.46.

The historical rank and industry rank for Medartis Holding AG's EV-to-EBIT or its related term are showing as below:

XSWX:MED' s EV-to-EBIT Range Over the Past 10 Years
Min: -594.74   Med: 102.92   Max: 419.05
Current: 120.46

During the past 11 years, the highest EV-to-EBIT of Medartis Holding AG was 419.05. The lowest was -594.74. And the median was 102.92.

XSWX:MED's EV-to-EBIT is ranked worse than
94.36% of 461 companies
in the Medical Devices & Instruments industry
Industry Median: 19.17 vs XSWX:MED: 120.46

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Medartis Holding AG's Enterprise Value for the quarter that ended in Dec. 2024 was CHF683.2 Mil. Medartis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was CHF7.9 Mil. Medartis Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 1.15%.


Medartis Holding AG EV-to-EBIT Historical Data

The historical data trend for Medartis Holding AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medartis Holding AG EV-to-EBIT Chart

Medartis Holding AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -197.88 163.60 -152.73 396.60 86.66

Medartis Holding AG Semi-Annual Data
Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -152.73 - 396.60 - 86.66

Competitive Comparison of Medartis Holding AG's EV-to-EBIT

For the Medical Devices subindustry, Medartis Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medartis Holding AG's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medartis Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medartis Holding AG's EV-to-EBIT falls into.


;
;

Medartis Holding AG EV-to-EBIT Calculation

Medartis Holding AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=949.723/7.884
=120.46

Medartis Holding AG's current Enterprise Value is CHF949.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medartis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was CHF7.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medartis Holding AG  (XSWX:MED) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Medartis Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=7.884/683.2186
=1.15 %

Medartis Holding AG's Enterprise Value for the quarter that ended in Dec. 2024 was CHF683.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medartis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was CHF7.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medartis Holding AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Medartis Holding AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Medartis Holding AG Business Description

Traded in Other Exchanges
Address
Hochbergerstrasse 60E, Basel, CHE, 4057
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from EMEA and also has a presence in APAC, USA, LATAM, and North America.